Epigenomics' tamoxifen response study "inconclusive"
This article was originally published in Clinica
Shares in Epigenomics fell by over 15% this week (October 31) after the company reported "inconclusive" data from a key study evaluating its tamoxifen treatment response test for breast cancer. The setback is expected to delay the company's product by at least nine months and could potentially complicate its long-term DNA methylation development programme with partner Roche Diagnostics.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.